Stryker completes $4.94 billion Inari Medical acquisition

Today, Stryker Corporation (NYSE:SYK), a leader in the medical technology industry with a market capitalization of $146.87 billion, announced the completion of its acquisition of Inari Medical (TASE:PMCN), Inc., marking a significant expansion in its product portfolio.

The transaction, which was finalized today, involved a cash consideration of approximately $4.94 billion. According to InvestingPro analysis, Stryker maintains a strong financial health rating and operates with a moderate level of debt.

The acquisition was carried out through a merger with Stryker’s wholly owned subsidiary, Eagle 1 Merger Sub, Inc., resulting in Inari Medical becoming a part of Stryker. This strategic move follows the execution of the Merger Agreement on January 6, 2025, and the subsequent joinder by Merger Sub on January 7, 2025.

The merger was conducted under Section 251(h) of the General Corporation Law of the State of Delaware, with Inari Medical continuing as the surviving corporation. The agreement terms were not disclosed in full detail, but the substantial cash transaction underscores Stryker’s commitment to enhancing its offerings in the medical instruments and apparatus sector.

With annual revenue of $22.59 billion and strong cash flows, Stryker has demonstrated its ability to execute strategic acquisitions while maintaining financial stability. InvestingPro subscribers can access detailed financial analysis and 14 additional ProTips about Stryker’s market position and growth potential.

Stryker, headquartered in Portage, Michigan, is well-known for its innovative products and services in orthopaedics, medical and surgical, and neurotechnology and spine that help improve patient and hospital outcomes. The addition of Inari Medical is expected to complement Stryker’s existing business and support its growth strategy.

The financial details of the merger were initially made public in Stryker’s Current Report on Form 8-K dated January 7, 2025. The completion of this acquisition is anticipated to have a meaningful impact on Stryker’s operational capabilities and market reach.

This news is based on a press release statement and provides an overview of the key facts related to the acquisition without any speculative insights. Currently trading near its 52-week high at $385.61, Stryker’s stock has shown a 13.58% return over the past six months.

The financial markets will continue to observe how this acquisition will influence Stryker’s performance on the New York Stock Exchange, where its common stock and various notes are traded under the symbols SYK, SYK27, SYK28, SYK29, SYK30, SYK31, SYK32, and SYK36, respectively. For comprehensive analysis and detailed valuation metrics, investors can access Stryker’s complete Pro Research Report on InvestingPro.

In other recent news, Stryker Corporation reported robust financial results for the fourth quarter of 2024, with sales reaching $6.44 billion, surpassing both Stifel’s and consensus estimates. The company’s earnings per share (EPS) also exceeded expectations, coming in at $4.01.

Following these strong results, Stifel analysts raised their price target for Stryker shares to $440, maintaining a "Buy" rating, while Truist Securities increased their target to $413, holding a "Hold" rating. Stryker also announced a 5.0% increase in its quarterly dividend to $0.84 per share, reflecting its financial health and commitment to shareholder returns.

Additionally, Stryker completed a $3 billion debt offering to fund its planned acquisition of Inari Medical, Inc., with the transaction expected to be finalized by 2025, contingent on certain conditions. The company also disclosed the upcoming retirement of board member Allan Golston, with no successor announced yet.

In a strategic move, Stryker plans to sell its Spine Implant business, which generated $707 million in revenue in 2024, aligning with its focus on higher-growth areas. These recent developments highlight Stryker’s proactive approach to managing its financial and operational strategies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.